GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Cephalexin

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

UCSF - cephalexin: bacteremia and IHD

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Label maximum differs from institution-specific bacteremia dosing

The KEFLEX renal table caps the daily dose in moderate impairment. UCSF uses a different high-dose strategy for selected gram-negative bloodstream infection; Stanford also has a distinct HD regimen.

What to reconcile: The indication and regimen must stay together. Do not average the doses or relabel the bloodstream-infection schedule as a general renal dose.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Label daily cap versus indication-specific institutional bloodstream doses

KEFLEX limits total daily dose to 1 g at CrCl 30-59 and has insufficient HD adjustment information. UCSF uses higher selected Gram-negative bloodstream-infection doses and supplies an intermittent-HD row.

What to reconcile: Assess infection eligibility, organism susceptibility, patient setting and institutional policy. Keep the complete institutional regimen separate from the label; do not transfer the bloodstream schedule to routine cystitis or children.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF - cephalexin: bacteremia and IHD

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For Gram-negative bloodstream infection, the fully populated renal row gives oral doses at renal-function bands >50 / 30-50 / 15-29 / <15 mL/min of 1 g four times daily / 1 g three times daily / 1 g twice daily / 500 mg three times daily.

During IHD, most indications use 250 mg twice daily; uncomplicated cystitis or streptococcal pharyngitis uses 250 mg daily; Gram-negative bloodstream infection uses 500 mg twice daily. The continuous-HD cells provide no regimen.

Other non-dialysis rows have merged or incompletely aligned cells in the retrieved representation. They were not converted into guessed renal-column assignments.

RDM30-013-cephalexin-1 · Source locator: UCSF - cephalexin: bacteremia and IHD; renal/dosing sections and stated qualifiers

Source-specific limits

This imported card covers the unambiguous bacteremia row and IHD rows; it is not the complete set of cephalexin indications.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/cephalexin
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
fc3d135816b24a6b61a8aa6cef3d5a3ba629cce23e047e4107d9aa6dd8d5694e

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cephalexin&s1=RDM30-013-cephalexin&h1=37bc51b7a3711b06d058b3b79d8bb672c532b80576153ed8c06197332c05c0e6